

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

LN-308

RRID:CVCL_0394

Type: Cell Line

Proper Citation

RRID:CVCL_0394

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0394

Proper Citation: RRID:CVCL_0394

Description: Cell line LN-308 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Astrocytoma

Defining Citation: [PMID:2990147](#), [PMID:7693337](#), [PMID:9842975](#), [PMID:10416987](#), [PMID:11351043](#), [PMID:14614447](#), [PMID:14655754](#), [PMID:17595512](#), [PMID:20504876](#), [PMID:20593219](#), [PMID:22570425](#), [PMID:25984343](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LN-308

Synonyms: LN 308, LN308, LNZ-308, LNZ 308, LNZ308, LN-Z308

Cross References: BTO:BTO_0004457, EFO:EFO_0022714, MCCL:MCC:0000289, BioGRID_ORCS_Cell_line:406, BioSample:SAMN10988416, cancercellines:CVCL_0394, Cell_Model_Passport:SIDM00682, Cosmic:849863, Cosmic:2367499, Cosmic:2516023, DepMap:ACH-000760, IARC_TP53:22502, Pharmacodb:LNZ308_852_2019, PRIDE:PXD008984, Wikidata:Q54902775

ID: CVCL_0394

Record Creation Time: 20220427T220731+0000

Record Last Update: 20260904T014545+0000

Ratings and Alerts

No rating or validation information has been found for LN-308.

No alerts have been found for LN-308.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

DeAngelo SL, et al. (2025) Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer. *Cancer research*, 85(15), 2788.

Sallbach J, et al. (2024) The cell cycle inhibitor p21CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 181, 117634.

Merk DJ, et al. (2024) Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. *Genome biology*, 25(1), 301.

Jane EP, et al. (2023) Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas. *Molecular oncology*, 17(9), 1821.

Nguyen TT, et al. (2023) Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA repair protein MPG. *Molecular oncology*, 17(9), 1744.

Hanisch D, et al. (2022) Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression. *Cell death & disease*, 13(4), 293.

Zhang M, et al. (2020) Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma. *Frontiers in genetics*, 11, 441.

Berberich A, et al. (2020) LAPTM5-CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance. *Frontiers in oncology*, 10, 747.

Zhang M, et al. (2020) Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. *Frontiers in genetics*, 11, 363.

Jameson NM, et al. (2019) Intron 1-Mediated Regulation of EGFR Expression in EGFR-Dependent Malignancies Is Mediated by AP-1 and BET Proteins. *Molecular cancer research : MCR*, 17(11), 2208.

Aasland D, et al. (2019) Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF- κ B. *Cancer research*, 79(1), 99.

Nguyen CDL, et al. (2019) A sensitive and simple targeted proteomics approach to quantify transcription factor and membrane proteins of the unfolded protein response pathway in glioblastoma cells. *Scientific reports*, 9(1), 8836.

Happold C, et al. (2018) Transcriptional control of O6 -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. *Journal of neurochemistry*, 144(6), 780.